Literature DB >> 22013227

Incidence and human papillomavirus (HPV) type distribution of genital warts in a multinational cohort of men: the HPV in men study.

Gabriella M Anic1, Ji-Hyun Lee, Heather Stockwell, Dana E Rollison, Yougui Wu, Mary R Papenfuss, Luisa L Villa, Eduardo Lazcano-Ponce, Christine Gage, Roberto José C Silva, Maria L Baggio, Manuel Quiterio, Jorge Salmerón, Martha Abrahamsen, Anna R Giuliano.   

Abstract

BACKGROUND: Data on the natural history of human papillomavirus (HPV)-related genital warts (GWs) in men are sparse. We described the distribution of HPV types in incident GWs and estimated GW incidence and time from type-specific incident HPV infections to GW detection in a multinational cohort of men aged 18-70 years.
METHODS: Participants included 2487 men examined for GWs and tested for HPV every 6 months and followed up for a median of 17.9 months. Samples were taken from 112 men with incident GWs to test for HPV DNA by polymerase chain reaction.
RESULTS: Incidence of GWs was 2.35 cases per 1000 person-years, with highest incidence among men aged 18-30 years (3.43 cases per 1000 person-years). HPV 6 (43.8%), HPV 11 (10.7%), and HPV 16 (9.8%) were the genotypes most commonly detected in GWs. The 24-month cumulative incidence of GWs among men with incident HPV 6/11 infections was 14.6% (95% confidence interval [CI], 7.5%-21.1%). Median time to GW detection was 17.1 months (95% CI, 12.4-19.3 months), with shortest time to detection among men with incident infections with HPV 6/11 only (6.2 months; 95% CI, 5.6-24.2 months).
CONCLUSIONS: HPV 6/11 plays an important role in GW development, with the highest incidence and shortest time to detection among men with incident HPV 6/11 infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22013227      PMCID: PMC3209812          DOI: 10.1093/infdis/jir652

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  24 in total

1.  Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.

Authors:  Anna R Giuliano; Joel M Palefsky; Stephen Goldstone; Edson D Moreira; Mary E Penny; Carlos Aranda; Eftyhia Vardas; Harald Moi; Heiko Jessen; Richard Hillman; Yen-Hwa Chang; Daron Ferris; Danielle Rouleau; Janine Bryan; J Brooke Marshall; Scott Vuocolo; Eliav Barr; David Radley; Richard M Haupt; Dalya Guris
Journal:  N Engl J Med       Date:  2011-02-03       Impact factor: 91.245

2.  Assessing incidence and economic burden of genital warts with data from a US commercially insured population.

Authors:  Tracey Hoy; Puneet K Singhal; Vincent J Willey; Ralph P Insinga
Journal:  Curr Med Res Opin       Date:  2009-10       Impact factor: 2.580

3.  Natural history of genital warts.

Authors:  J D Oriel
Journal:  Br J Vener Dis       Date:  1971-02

4.  Development of genital warts after incident detection of human papillomavirus infection in young men.

Authors:  Yuzo Arima; Rachel L Winer; Qinghua Feng; James P Hughes; Shu-Kuang Lee; Michael E Stern; Sandra F O'Reilly; Laura A Koutsky
Journal:  J Infect Dis       Date:  2010-10-15       Impact factor: 5.226

5.  Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study.

Authors:  Anna R Giuliano; Ji-Hyun Lee; William Fulp; Luisa L Villa; Eduardo Lazcano; Mary R Papenfuss; Martha Abrahamsen; Jorge Salmeron; Gabriella M Anic; Dana E Rollison; Danelle Smith
Journal:  Lancet       Date:  2011-02-28       Impact factor: 79.321

6.  'Shame on you'--the psychosocial impact of genital warts.

Authors:  C Jeynes; M C Chung; R Challenor
Journal:  Int J STD AIDS       Date:  2009-08       Impact factor: 1.359

7.  Distribution of human papillomavirus types in anogenital warts of men.

Authors:  Paul K S Chan; Alfred C S Luk; Tommy N M Luk; Kwong-Fai Lee; Jo L K Cheung; King-Man Ho; Kuen-Kong Lo
Journal:  J Clin Virol       Date:  2008-12-18       Impact factor: 3.168

8.  Circumcision and sexual behavior: factors independently associated with human papillomavirus detection among men in the HIM study.

Authors:  Anna R Giuliano; Eduardo Lazcano; Luisa Lina Villa; Roberto Flores; Jorge Salmeron; Ji-Hyun Lee; Mary Papenfuss; Martha Abrahamsen; Maria Luiza Baggio; Roberto Silva; Manuel Quiterio
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

9.  The health and economic burden of genital warts in a set of private health plans in the United States.

Authors:  Ralph P Insinga; Erik J Dasbach; Evan R Myers
Journal:  Clin Infect Dis       Date:  2003-05-19       Impact factor: 9.079

10.  External genital warts: diagnosis, treatment, and prevention.

Authors:  D J Wiley; John Douglas; Karl Beutner; Tom Cox; Kenneth Fife; Anna-Barbara Moscicki; Lynne Fukumoto
Journal:  Clin Infect Dis       Date:  2002-10-15       Impact factor: 9.079

View more
  27 in total

1.  Oral and oropharyngeal papillomas are not associated with high-risk human papillomavirus infection.

Authors:  Miroslaw Snietura; Roman Lamch; Agnieszka Kopec; Dariusz Waniczek; Wirginia Likus; Dariusz Lange; Jaroslaw Markowski
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-06-21       Impact factor: 2.503

2.  Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics-Sexually Transmitted Disease Surveillance Network, United States, 2010-2016.

Authors:  Laura M Mann; Eloisa Llata; Elaine W Flagg; Jaeyoung Hong; Lenore Asbel; Juli Carlos-Henderson; Roxanne P Kerani; Robert Kohn; Preeti Pathela; Christina Schumacher; Elizabeth A Torrone
Journal:  J Infect Dis       Date:  2019-04-16       Impact factor: 5.226

3.  Genital Human Papillomavirus Infection Progression to External Genital Lesions: The HIM Study.

Authors:  Staci L Sudenga; Donna J Ingles; Christine M Pierce Campbell; Hui-Yi Lin; William J Fulp; Jane L Messina; Mark H Stoler; Martha Abrahamsen; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano
Journal:  Eur Urol       Date:  2015-06-06       Impact factor: 20.096

Review 4.  Male genital premalignant dermatoses.

Authors:  Oliver Kayes; Majid Shabbir; Suks Minhas
Journal:  Curr Urol Rep       Date:  2012-12       Impact factor: 3.092

5.  Declines in Anogenital Warts Among Age Groups Most Likely to Be Impacted by Human Papillomavirus Vaccination, United States, 2006-2014.

Authors:  Elaine W Flagg; Elizabeth A Torrone
Journal:  Am J Public Health       Date:  2017-11-21       Impact factor: 9.308

6.  The Impact of Human Papillomavirus Catch-Up Vaccination in Australia: Implications for Introduction of Multiple Age Cohort Vaccination and Postvaccination Data Interpretation.

Authors:  Mélanie Drolet; Jean-François Laprise; Julia M L Brotherton; Basil Donovan; Christopher K Fairley; Hammad Ali; Élodie Bénard; Dave Martin; Marc Brisson
Journal:  J Infect Dis       Date:  2017-12-05       Impact factor: 5.226

Review 7.  Genital HPV infection and related lesions in men.

Authors:  Gabriella M Anic; Anna R Giuliano
Journal:  Prev Med       Date:  2011-10       Impact factor: 4.018

8.  Cutaneous human papillomavirus types detected on the surface of male external genital lesions: a case series within the HPV Infection in Men Study.

Authors:  Christine M Pierce Campbell; Jane L Messina; Mark H Stoler; Drazen M Jukic; Massimo Tommasino; Tarik Gheit; Dana E Rollison; Laura Sichero; Bradley A Sirak; Donna J Ingles; Martha Abrahamsen; Beibei Lu; Luisa L Villa; Eduardo Lazcano-Ponce; Anna R Giuliano
Journal:  J Clin Virol       Date:  2013-10-16       Impact factor: 3.168

9.  Phylogenetic considerations in designing a broadly protective multimeric L2 vaccine.

Authors:  Subhashini Jagu; Kihyuck Kwak; John T Schiller; Douglas R Lowy; Harold Kleanthous; Kirill Kalnin; Chenguang Wang; Hsu-Kun Wang; Louise T Chow; Warner K Huh; Kilvani S Jaganathan; Sudha V Chivukula; Richard B S Roden
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

10.  Distribution of genital wart human papillomavirus genotypes in China: a multi-center study.

Authors:  Lihong Chang; Puwa Ci; Jufang Shi; Kan Zhai; Xiaoli Feng; Danny Colombara; Wei Wang; Youlin Qiao; Wen Chen; Yuping Wu
Journal:  J Med Virol       Date:  2013-07-16       Impact factor: 2.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.